{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:37:53Z","timestamp":1758807473406},"reference-count":5,"publisher":"BMJ","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.bmj.com\/company\/legal-information\/terms-conditions\/legal-information\/tdm-licencepolicy"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ"],"DOI":"10.1136\/bmj.p2604","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T18:40:13Z","timestamp":1699382413000},"page":"p2604","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Evolving use of recreational drugs in UK\u2014nitazenes and xylazine"],"prefix":"10.1136","author":[{"given":"Limon Khatun","family":"Nahar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"key":"2023110806100756000_383.nov07_14.p2604.1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.p2280"},{"key":"2023110806100756000_383.nov07_14.p2604.2","unstructured":"Medicines and Healthcare Products Regulatory Agency. Potent synthetic opioids implicated in heroin overdoses and deaths. Jul 2023. www.cas.mhra.gov.uk\/ViewandAcknowledgment\/ViewAlert.aspx?AlertID=103236."},{"key":"2023110806100756000_383.nov07_14.p2604.3","unstructured":"Advisory Council on the Misuse of Drugs. ACMD advice on 2-benzyl benzimidazole and piperidine benzimidazolone opioids. Feb 2023. www.gov.uk\/government\/publications\/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids\/acmd-advice-on-2-benzyl-benzimidazole-and-piperidine-benzimidazolone-opioids-accessible-version."},{"key":"2023110806100756000_383.nov07_14.p2604.4","unstructured":"World Health Organization. Critical review report: Protonitazene (Expert Committee on Drug Dependence). Oct 2022. https:\/\/cdn.who.int\/media\/docs\/default-source\/controlled-substances\/45th-ecdd\/protonitazene_draft.pdf."},{"key":"2023110806100756000_383.nov07_14.p2604.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.forsciint.2021.110686"}],"container-title":["BMJ"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/data.bmj.org\/tdm\/10.1136\/bmj.p2604","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmj.p2604","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T14:10:21Z","timestamp":1699452621000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.bmj.com\/lookup\/doi\/10.1136\/bmj.p2604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":5,"alternative-id":["10.1136\/bmj.p2604"],"URL":"https:\/\/doi.org\/10.1136\/bmj.p2604","relation":{},"ISSN":["1756-1833"],"issn-type":[{"value":"1756-1833","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,7]]}}}